Get all company financials in excel:

Download Sample   $19.99

More Charts

Krka dd Novo Mesto is a Slovenia-based company involved in the production and sale of prescription pharmaceuticals, non-prescription products and animal health products. The Company operates through four segments: Prescription Pharmaceuticals that includes medicines for the treatment of cardiovascular diseases, alimentary tract and metabolism and drugs for diseases of the central nervous system, among others; Non-prescription Products, providing vitamins and minerals, cough and cold products, analgesics, sore throat products, among others; Animal Health Products, which offers general anti-infectives and antiparasitics for animals; Health Resort and Tourist Services. Krka sells approximately 92% of its products in more than 70 countries worldwide, mainly in Central and Eastern Europe

Finance

Krka has been growing its sales by a year on average in the last 5 years. EBITDA has grown by 0% during that time to total of in 2015, or of sales. That’s compared to % average margin seen in last five years.

The company netted in 2015 implying ROE of and ROCE of . Again, the average figures were % and %, respectively when looking at the previous 5 years.

Krka’s net debt amounted to at the end of 2015, or of equity. When compared to EBITDA, net debt was x, up when compared to average of x seen in the last 5 years.

Valuation

Krka stock traded at per share at the end of 2015 resulting in a market capitalization of . Over the previous five years, stock price grew by 0% or % a year on average. The closing price put stock at a 12-month trailing EV/EBITDA of x and price to earnings (PE) of x as of 2015.